Cabotegravir

Modify Date: 2024-01-02 20:01:15

Cabotegravir structure	Common Name	Cabotegravir
	CAS Number	1051375-10-0	Molecular Weight	405.352
	Density	1.6±0.1 g/cm3	Boiling Point	664.0±55.0 °C at 760 mmHg
	Molecular Formula	C₁₉H₁₇F₂N₃O₅	Melting Point	N/A
	MSDS	N/A	Flash Point	355.4±31.5 °C

Use of Cabotegravir

Cabotegravir is a potent HIV integrase inhibitor as an oral lead-in tablet and long-acting injectable for the treatment and prevention of HIV infection. Cabotegravir is an inhibitor of OAT1 (IC50 0.81 μM) and OAT3 (IC50 0.41 μM).IC50 value: 0.81 μM (OAT1), 0.41 μM (OAT3) [1]Target: OAT1, OAT3Cabotegravir is a potent HIV integrase inhibitor in clinical development as an oral lead-in tablet and long-acting injectable for the treatment and prevention of HIV infection.[2] Cabotegravir is an HIV-1 integrase inhibitor under development as a tablet for both oral lead-in therapy and long-acting (LA) injectable for intramuscular dosing.[3]

Name	SureCN82803
Synonym	More Synonyms

Description	Cabotegravir is a potent HIV integrase inhibitor as an oral lead-in tablet and long-acting injectable for the treatment and prevention of HIV infection. Cabotegravir is an inhibitor of OAT1 (IC50 0.81 μM) and OAT3 (IC50 0.41 μM).IC50 value: 0.81 μM (OAT1), 0.41 μM (OAT3) [1]Target: OAT1, OAT3Cabotegravir is a potent HIV integrase inhibitor in clinical development as an oral lead-in tablet and long-acting injectable for the treatment and prevention of HIV infection.[2] Cabotegravir is an HIV-1 integrase inhibitor under development as a tablet for both oral lead-in therapy and long-acting (LA) injectable for intramuscular dosing.[3]
Related Catalog	Signaling Pathways >> Metabolic Enzyme/Protease >> HIV Integrase Signaling Pathways >> Anti-infection >> HIV Research Areas >> Infection
References	[1]. Reese MJ, Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam. Xenobiotica. 2015 Sep 4:1-12. [2]. Reese MJ, et al. Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam. Xenobiotica. 2015 Sep 4:1-12. [3]. Bowers GD, Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans. Xenobiotica. 2015 Jul 1:1-16.

Description

Related Catalog

Signaling Pathways >> Metabolic Enzyme/Protease >> HIV Integrase

Signaling Pathways >> Anti-infection >> HIV

Research Areas >> Infection

References

[1]. Reese MJ, Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam. Xenobiotica. 2015 Sep 4:1-12.

[2]. Reese MJ, et al. Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam. Xenobiotica. 2015 Sep 4:1-12.

[3]. Bowers GD, Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans. Xenobiotica. 2015 Jul 1:1-16.

Density	1.6±0.1 g/cm3
Boiling Point	664.0±55.0 °C at 760 mmHg
Molecular Formula	C₁₉H₁₇F₂N₃O₅
Molecular Weight	405.352
Flash Point	355.4±31.5 °C
Exact Mass	405.113617
PSA	104.36000
LogP	-1.70
Vapour Pressure	0.0±2.1 mmHg at 25°C
Index of Refraction	1.661
Storage condition	-20℃